Immunome Inc. Reports Q2 2026 Financial Results

What Happened

• Immunome, Inc. announced its financial results for the quarter ended June 30, 2026 and provided a business update in a press release dated August 11, 2026. The company filed a Form 8‑K (Item 2.02) to disclose these results and incorporated the press release as Exhibit 99.1. The filing was signed by Max Rosett, Chief Financial Officer, on August 11, 2026.

Key Details

• Filing date: August 11, 2026 (Form 8‑K, Item 2.02).
• Reporting period: Quarter ended June 30, 2026 (Q2 2026).
• Disclosure: Press release attached as Exhibit 99.1 and incorporated by reference.
• Filing also references Exhibit 104 (Inline XBRL cover page data) under Item 9.01.

Why It Matters

• This Form 8‑K signals that Immunome has released its latest quarterly operating and financial results and provided an operational/business update — material information investors use to assess near‑term performance, cash runway and strategy execution. The 8‑K text points investors to the press release (Exhibit 99.1) for the specific figures and narrative; retail investors should review that press release and any accompanying financial statements or earnings materials to see revenue, expenses, guidance, or other metrics that could affect the stock.